Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma

• Published in: Cells (Basel, Switzerland) Switzerland), 2019-05, Vol.8 (5), p.494
• Main Authors: Zhang, Qiushuang, Xie, Chao, Wang, Dongyu, Yang, Yi, Liu, Hangfan, Liu, Kangdong, Zhao, Jimin, Chen, Xinhuan, Zhang, Xiaoyan, Yang, Wanjing, Li, Xiang, Tian, Fang, Dong, Ziming, Lu, Jing
• Format: Article
• Language: English
• Subjects: Angiogenesis; Animals; Antigens; Antitumor activity; Bone marrow; Cancer; Cancer immunotherapy; Cancer Vaccines - therapeutic use; Cell Line, Tumor; Colorectal carcinoma; Colorectal Neoplasms - therapy; Combined vaccines; Cytokines; Cytotoxicity; dendritic cell; Dendritic cells; Dendritic Cells - immunology; Endothelial cells; Female; Growth factors; human umbilical vein endothelial cell; Human Umbilical Vein Endothelial Cells; Humans; Immunotherapy; Laboratories; Lymphocytes T; Medical research; Membrane proteins; Metastases; Mice; Mice, Inbred BALB C; Solid tumors; Spleen; Tumor cells; Tumor microenvironment; Tumor Microenvironment - immunology; Tumors; Umbilical vein; Vaccination; vaccine; Vaccines; Vaccines, Combined - therapeutic use; γ-Interferon
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells8050494

Angiogenesis is essential for the development, growth, and metastasis of solid tumors. Vaccination with viable human umbilical vein endothelial cells (HUVECs) has been used for antitumor angiogenesis. However, the limited immune response induced by HUVECs hinders their clinical application. In the present study, we found that HUVECs induced by a tumor microenvironment using the supernatant of murine CT26 colorectal cancer cells exerted a better antiangiogenic effect than HUVECs themselves. The inhibitory effect on tumor growth in the induced HUVEC group was significantly better than that of the HUVEC group, and the induced HUVEC group showed a strong inhibition in CD31-positive microvessel density in the tumor tissues. Moreover, the level of anti-induced HUVEC membrane protein antibody in mouse serum was profoundly higher in the induced HUVEC group than in the HUVEC group. Based on this, the antitumor effect of a vaccine with a combination of induced HUVECs and dendritic cell-loading CT26 antigen (DC-CT26) was evaluated. Notably, the microvessel density of tumor specimens was significantly lower in the combined vaccine group than in the control groups. Furthermore, the spleen index, the killing effect of cytotoxic T lymphocytes (CTLs), and the concentration of interferon-γ in the serum were enhanced in the combined vaccine group. Based on these results, the combined vaccine targeting both tumor angiogenesis and tumor cells may be an attractive and effective cancer immunotherapy strategy.